[541] Functional Cardiac Imaging


Using a translational approach, our research group's interests are in MR imaging of molecular and cellular processes. Our uniqueness lies in the development of an imaging strategy based on clinical MRI systems for examining small animals, as well as using the same tools, systems and protocols for patients.

Cardiac Imaging

One long-standing area of research concerns cardiac imaging. We have developed several models of occlusion / reperfusion in rats to be able to image by MRI the effect and consequences of ischemia. We showed that it was possible to measure the area at risk in rat using manganese and to view, noninvasively, migration of monocytes to the site of a myocardial infarction. After validating a method for measuring function and size of myocardial infarction in mice, we investigate the potential of new contrast-based MRI with iron oxide for the evaluation of the inflammatory response in myocardial infarction.

Arthritis: NanoDiaRA project

A second line of research concerns molecular imaging with iron particles in MR imaging in rheumatoid arthritis based on the European project NanoDiaRA (FP7-NMP-2008-LARGE-2). This project aims to develop new contrast agents and diagnostic derivatives of iron oxide particles for the early diagnosis of rheumatoid arthritis and osteoarthritis. Our group leads the imaging component (Work Package 2) validating the development of new iron particles produced by the European partners of the consortium (The group is also partner in a European Commission 7th Framework Programme for Research project. The main objective of this large-scale integrating project is the development of modified superparamagnetic nanoparticles as a diagnostic tool for the detection of early stages of arthritis. In addition to research, the project will consider the social, ethical and legal aspects of applying nanotechnology for medical purposes. The University of Geneva is responsible for in-vivo imaging of the disease in small animal models using MRI and uCT. The detections and quantification of new iron oxide nanoparticle contrast agents, both non-specific and specific, are investigated to help with early diagnostics and possible drug delivery methods.)

group publications